All In Biotech

Drug Trial Radar · NCT06183736

CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency

A Single-arm, Open-label, Multicenter, Phase II Study of CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency

Last checked: Nov 19, 2026Latest source record: Dec 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

98

Planned (sponsor's estimate)

Start

Dec 20, 2023

Primary completion

Jun 30, 2025

Study completion Jun 30, 2027

Sponsor

Lead sponsor
Convalife (Shanghai) Co., Ltd.Industry
Sponsor type
Industry
First posted
Dec 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-arm, open-label, multicenter, phase II study of CVL237 tablets in the treatment of advanced solid tumors with PTEN deficiency. It is planned to enroll patients with PTEN deficiency advanced solid tumors of different tumor types (PTEN deficiency gastric cancer, prostate cancer, endometrial cancer, colorectal cancer, lung cancer, breast cancer and melanoma etc.) to evaluate the preliminary efficacy, safety and pharmacokinetic profile of CVL237 tablets in patients with PTEN deficiency advanced solid tumors of different tumor types.

Conditions

  • Advanced Solid Tumors

Interventions

  • CVL237 tabletsDrug

    CVL237 tablets, 200 mg, taken with food once daily for 28 consecutive days as a treatment cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR) in patients with PTEN deficiency as assessed according to RECIST v1.1Time frame: Throughout the study for approximately 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Li Ning

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.